Literature DB >> 2750267

Fluorometric assay for the measurement of viral neuraminidase in influenza vaccines.

C R Lambré1, S Chauvaux, Y Pilatte.   

Abstract

Influenza viruses have two surface glycoproteins: haemagglutinin and neuraminidase which are capable of inducing a significant antibody response following vaccination. All neuraminidases from different strains of influenza A and B viruses are able to hydrolyse alpha-ketosidic linkages between N-acetylneuraminic (sialic) acid and other carbohydrates. In this report, the neuraminidase activity was assayed in various influenza vaccines by using a fluorogenic substrate: the sodium salt of 2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid. This method was reliable (variation less than 8%) and more sensitive (100 to 1000 times) in less time (incubation time = 15 min) than the Warren assay. Therefore, the method is suitable for the control of the sialidase activity during the processing of influenza vaccines.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2750267     DOI: 10.1016/0264-410x(89)90045-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Dose-dependent changes in influenza virus-infected dendritic cells result in increased allogeneic T-cell proliferation at low, but not high, doses of virus.

Authors:  SangKon Oh; J Michael McCaffery; Maryna C Eichelberger
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine.

Authors:  Steven Rockman; Lorena E Brown; Ian G Barr; Brad Gilbertson; Sue Lowther; Anatoly Kachurin; Olga Kachurina; Jessica Klippel; Jesse Bodle; Martin Pearse; Deborah Middleton
Journal:  J Virol       Date:  2013-01-02       Impact factor: 5.103

3.  Influenza A (N1-N9) and Influenza B (B/Victoria and B/Yamagata) Neuraminidase Pseudotypes as Tools for Pandemic Preparedness and Improved Influenza Vaccine Design.

Authors:  Kelly A S da Costa; Joanne Marie M Del Rosario; Matteo Ferrari; Sneha Vishwanath; Benedikt Asbach; Rebecca Kinsley; Ralf Wagner; Jonathan L Heeney; George W Carnell; Nigel J Temperton
Journal:  Vaccines (Basel)       Date:  2022-09-14

4.  Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.

Authors:  Brendon Y Chua; Chinn Yi Wong; Edin J Mifsud; Kathryn M Edenborough; Toshiki Sekiya; Amabel C L Tan; Francesca Mercuri; Steve Rockman; Weisan Chen; Stephen J Turner; Peter C Doherty; Anne Kelso; Lorena E Brown; David C Jackson
Journal:  mBio       Date:  2015-10-27       Impact factor: 7.867

5.  A neuraminidase activity-based microneutralization assay for evaluating antibody responses to influenza H5 and H7 vaccines.

Authors:  Hui Zhao; Kangwei Xu; Zheng Jiang; Ming Shao; Shuzhen Liu; Xuguang Li; Junzhi Wang; Changgui Li
Journal:  PLoS One       Date:  2018-11-15       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.